Clinical Trial

Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

Name: Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer — clinical trial record (NCT06818773)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of inetetamab in combination with chemotherapy ± immunotherapy as a first-line treatment for HER2-positive advanced biliary tract cancer, providing theoretical evidence and practical guidance for further optimizing treatment regimens and improving therapeutic outcomes.

Trial Details

NCT Number	NCT06818773
Lead Sponsor	Eastern Hepatobiliary Surgery Hospital
Conditions	Metastatic Biliary Tract Cancer, HER2 Positive
Enrollment	35 participants
Start Date	2025-02
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-02-10